AI English summary of an SEC filing — figures as filed
Abbott Laboratories ABTThe company said total net sales rose 7.4% in Q3 2024, excluding the impact of foreign exchange. COVID-19 testing-related sales were $265 million in Q3, compared with $305 million a year earlier. It said the stronger U.S. dollar reduced total sales by 2.5%.
Key points
AI summaryThe company said total net sales rose 7.4% in Q3 2024, excluding the impact of foreign exchange. COVID-19 testing-related sales were $265 million in Q3, compared with $305 million a year earlier. It said the stronger U.S. dollar reduced total sales by 2.5%.
The company said Medical Devices sales, excluding the impact of foreign exchange, rose 13.6% in the first 9 months of 2024. CGM systems sales totaled $4.7 billion, up 21.4% excluding foreign exchange, compared with $3.9 billion in the same period a year earlier.
The company said its gross profit margin percentage was 51.4% in Q3 2024, compared with 49.7% a year earlier. It said higher pricing and gross margin improvement initiatives partially offset the unfavorable effect of foreign exchange. R&D expenses in Q3 increased by $41 million to $713 million.
The company said net cash from operating activities for the first 9 months of 2024 was about $5.7 billion, an increase of $1.5 billion from the prior year. It repurchased about 7 million shares for $750 million in Q3, and on October 11, 2024 its board of directors authorized repurchases of up to $7 billion.
Key figures
Quarter ended September 30, 2024
- Revenue
- $10.6B
- Operating income
- $1.9B
- Net income
- $1.6B
- EPS
- $0.94
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q3 2024 Net Sales and COVID-19 Testing Sales
The company said total net sales rose 7.4% in Q3 2024, excluding the impact of foreign exchange. COVID-19 testing-related sales were $265 million in Q3, compared with $305 million a year earlier. It said the stronger U.S. dollar reduced total sales by 2.5%.
Source · Based on the MD&A text of the filing
Medical Devices Sales Rise in First 9 Months
The company said Medical Devices sales, excluding the impact of foreign exchange, rose 13.6% in the first 9 months of 2024. CGM systems sales totaled $4.7 billion, up 21.4% excluding foreign exchange, compared with $3.9 billion in the same period a year earlier.
Source · Based on the MD&A text of the filing
Gross Margin and R&D Expense Changes
The company said its gross profit margin percentage was 51.4% in Q3 2024, compared with 49.7% a year earlier. It said higher pricing and gross margin improvement initiatives partially offset the unfavorable effect of foreign exchange. R&D expenses in Q3 increased by $41 million to $713 million.
Source · Based on the MD&A text of the filing
Operating Cash Flow and Share Buyback Authorization
The company said net cash from operating activities for the first 9 months of 2024 was about $5.7 billion, an increase of $1.5 billion from the prior year. It repurchased about 7 million shares for $750 million in Q3, and on October 11, 2024 its board of directors authorized repurchases of up to $7 billion.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…